Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Abiraterone + Apalutamide + Gonadorelin + Prednisone|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Abiraterone||Zytiga||CB7630||Hormone - Anti-androgens 26||Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov).|
|Apalutamide||Erleada||ARN-509|JNJ-56021927||Hormone - Anti-androgens 26||Erleada (apalutamide) is a second-generation antiandgrogen, that binds to the androgen receptor (AR) and inhibits downstream signaling, potentially resulting in decreased growth of AR-expressing tumors (PMID: 22266222, PMID: 23337756). Erleada (apalutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (FDA.gov).|
|Gonadorelin||Dirigestran|GnRH|LHRHA|AY-24031||Hormone Antineoplastics 5||Gonadorelin is a synthetic version of gonatotropin-releasing hormone (GnRH) that binds GnRH receptors and induces gonatotropic hormone release, and leads to down-regulation of GnRH receptor expression and reduced hormone release following sustained exposure (NCI Drug Dictionary).|
|Prednisone||Adasone||Dehydrocortisone||Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03141671||Phase II||Bicalutamide + Gonadorelin Abiraterone + Apalutamide + Gonadorelin + Prednisone||Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)||Recruiting|